GHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GH Research PLC (GHRS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong progress in clinical trials, positive analyst sentiment, and hedge fund interest outweigh the lack of immediate technical signals and financial profitability. The stock has significant long-term potential in the treatment-resistant depression market.
The MACD is below zero and negatively contracting, indicating a weak momentum. RSI is neutral at 44.566, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 14.352, with support at 13.145 and resistance at 15.559.
Publication of Phase 2b trial results in JAMA Psychiatry showing significant efficacy of GH001 in treatment-resistant depression.
Upcoming publication in Psychopharmacology Bulletin highlighting GH001's efficacy regardless of prior antidepressant failures.
Analysts have raised price targets significantly, with strong confidence in the regulatory path and long-term sales potential.
Hedge funds have increased their buying activity by 735.47% over the last quarter.
The company is not yet profitable, with a net income of -$14.14M in Q4
Technical indicators do not show a strong buy signal, and there is a 30% chance of a -4.18% drop in the next day.
No recent congress trading data or insider buying trends.
In Q4 2025, the company showed a 60.61% YoY improvement in net income to -$14.14M and a 35.29% YoY improvement in EPS to -$0.23. However, revenue and gross margin remain at zero, indicating the company is still in the development phase.
Analysts are highly optimistic about GHRS, with Guggenheim, Citizens, and RBC Capital raising price targets to $34, $42, and $40, respectively. They highlight strong clinical progress and long-term sales potential for GH001 in the treatment-resistant depression market.
